TY - CHAP
T1 - CTCs in metastatic breast cancer
AU - Giordano, Antonio
AU - Cristofanilli, Massimo
N1 - Copyright:
Copyright 2012 Elsevier B.V., All rights reserved.
PY - 2012
Y1 - 2012
N2 - Circulating tumor cells (CTCs), enumerated by the Food and Drugs Administration-cleared CellSearch® system, are an independent prognostic factor of progression-free survival (PFS) and overall survival (OS) in metastatic breast cancer (MBC) patients. Several published papers demonstrated the poor prognosis for MBC patients who presented basal CTC count ≥5 in 7.5 mL of blood. Therefore, the enumeration of CTCs during treatment for MBC provides a tool with the ability to predict progression of disease earlier than standard timing of anatomical assessment using conventional radiological tests. Randomized clinical trials are ongoing to demonstrate whether CTCs detected by CellSearch® may help to guide treatments in MBC patients and improve prognosis. Moreover, the ability to perform molecular characterization of CTCs might identify a new druggable target in MBC patients. For example, the RT-PCR-based approach AdnaTest BreastCancerSelect™ showed a high discordance rate in receptor expression between the primary tumors and CTCs. Theoretically, the phenotypic analysis of CTCs can represent a "liquid" biopsy of breast tumor that is able to identify a new potential target against the metastatic disease.
AB - Circulating tumor cells (CTCs), enumerated by the Food and Drugs Administration-cleared CellSearch® system, are an independent prognostic factor of progression-free survival (PFS) and overall survival (OS) in metastatic breast cancer (MBC) patients. Several published papers demonstrated the poor prognosis for MBC patients who presented basal CTC count ≥5 in 7.5 mL of blood. Therefore, the enumeration of CTCs during treatment for MBC provides a tool with the ability to predict progression of disease earlier than standard timing of anatomical assessment using conventional radiological tests. Randomized clinical trials are ongoing to demonstrate whether CTCs detected by CellSearch® may help to guide treatments in MBC patients and improve prognosis. Moreover, the ability to perform molecular characterization of CTCs might identify a new druggable target in MBC patients. For example, the RT-PCR-based approach AdnaTest BreastCancerSelect™ showed a high discordance rate in receptor expression between the primary tumors and CTCs. Theoretically, the phenotypic analysis of CTCs can represent a "liquid" biopsy of breast tumor that is able to identify a new potential target against the metastatic disease.
UR - http://www.scopus.com/inward/record.url?scp=84860593757&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860593757&partnerID=8YFLogxK
U2 - 10.1007/978-3-642-28160-0_18
DO - 10.1007/978-3-642-28160-0_18
M3 - Chapter
C2 - 22527507
AN - SCOPUS:84860593757
SN - 9783642281594
T3 - Recent Results in Cancer Research
SP - 193
EP - 201
BT - Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer
A2 - Ignatiadis, Michail
A2 - Sotiriou, Christos
A2 - Pantel, Klaus
ER -